atopic dermatitis Archives -

Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe

Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis

https://pharmaphorum.com/r-d/almirall-lilly-lebrikizumab-offers-potential-long-term-management-of-atopic-dermatitis/

10 Tips for Digital Asset Management Success

Digital/ News/ Press Releases

DiME digital measure is nocturnal scratch for atopic dermatitis

Nicole Raleigh atopic dermatitis, dermatology, digital endpoint, digital health, Digital Medicine Society (DiMe), eczema, Medical, nocturnal scratch, product development 0 Comment

The Digital Medicine Society (DiME) is today releasing a new set of open-access resources to advance the use

DiME digital measure is nocturnal scratch for atopic dermatitis

https://pharmaphorum.com/digital/dime-digital-measure-is-nocturnal-scratch-for-atopic-dermatitis/

Partner content/ Press releases/ Sales and Marketing

Independent expert analysis of the pipeline in 5 disease areas

Fishawack Marketing alopecia areata, atopic dermatitis, dermatology, psoriasis, vitiligo 0 Comment

Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and

Independent expert analysis of the pipeline in 5 disease areas

https://pharmaphorum.com/partner-content/independent-expert-analysis-of-the-pipeline-in-5-disease-areas/

Sales and Marketing/ Views & Analysis/ Views and analysis/ White Papers/ Whitepapers

Ensuring successful digital outreach and retention in atopic dermatitis trials

mike.hammerton@pharmaphorum.com atopic dermatitis, clariness, clinical trials, patient recruitment 0 Comment

Trial organisers face intense competition to find and recruit eligible patients for atopic dermatitis studies. With more than

Ensuring successful digital outreach and retention in atopic dermatitis trials

https://pharmaphorum.com/whitepapers/ensuring-successful-digital-outreach-and-retention-atopic-dermatitis-trials/

Digital/ News/ News

Sidekick and Pfizer prep launch of DTx for atopic dermatitis

Phil Taylor atopic dermatitis, dermatology, digital, digital health, digital therapeutics, Pfizer, Sidekick Health 0 Comment

A long-running partnership between digital therapeutics (DTx) developer Sidekick Health and Pfizer has resulted in a new app

Sidekick and Pfizer prep launch of DTx for atopic dermatitis

https://pharmaphorum.com/news/sidekick-and-pfizer-prep-launch-of-dtx-for-atopic-dermatitis/

News/ News/ Sales and Marketing

Leo puts target on Dupixent in US as FDA clears tralokinumab

Phil Taylor AbbVie, atopic dermatitis, Cibinqo, dermatology, Eli Lilly, lebrikizumab, LEO Pharma, Olumiant, Pfizer, Regeneron, regulatory approval, Rinvoq, Sanofi, tralokinumab 0 Comment

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA

Leo puts target on Dupixent in US as FDA clears tralokinumab

https://pharmaphorum.com/news/leo-puts-target-on-dupixent-in-us-as-fda-clears-tralokinumab/

Digital/ News/ News

Pharma group will develop ‘digital endpoint’ for atopic dermatitis

Phil Taylor AbbVie, atopic dermatitis, clinical trials, digital, digital endpoint, digital health, Janssen, Novartis, Pfizer, UCB 0 Comment

The development of digital medicine requires valid endpoints that can be used in clinical trials, and a consortium

Pharma group will develop ‘digital endpoint’ for atopic dermatitis

https://pharmaphorum.com/news/pharma-group-will-develop-digital-endpoint-for-atopic-dermatitis/

News/ News/ R&D

Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema

Phil Taylor amlitelimab, atopic dermatitis, dermatology, Kymab, OX40, Sanofi 0 Comment

Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category

Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema

https://pharmaphorum.com/news/key-drug-in-sanofis-1-45bn-kymab-buyout-shows-promise-in-eczema/

Market Access/ News/ News

Pfizer gets first approval, in UK, for Xeljanz follow-up Cibinqo

Phil Taylor abrocitinib, atopic dermatitis, Cibinqo, JAK inhibitor, MHRA, Pfizer, regulatory approval, Xeljanz 0 Comment

Pfizer has claimed its first regulatory approval worldwide for Cibinqo, its JAK inhibitor for atopic dermatitis, from the

Pfizer gets first approval, in UK, for Xeljanz follow-up Cibinqo

https://pharmaphorum.com/news/pfizer-gets-first-approval-in-uk-for-xeljanz-follow-up-cibinqo/

Trending

atopic dermatitis

Login